Post COVID-19 vaccination Guillain-Barre syndrome: three cases
Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy. In two-thirds of patients, it is preceded by an upper respiratory or gastrointestinal tract infection. Temporally associated cases of GBS following COVID-19 vaccination have been described with different COVID-19 vaccines...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2045153 |
| _version_ | 1827806476176982016 |
|---|---|
| author | Seyedehnarges Tabatabaee Fatemeh Rezania Sayed Mohammed Jawad Alwedaie Ensieh Malekdar Zahra Badi Seyed Mohammad Tabatabaei Zahra Mirzaasgari |
| author_facet | Seyedehnarges Tabatabaee Fatemeh Rezania Sayed Mohammed Jawad Alwedaie Ensieh Malekdar Zahra Badi Seyed Mohammad Tabatabaei Zahra Mirzaasgari |
| author_sort | Seyedehnarges Tabatabaee |
| collection | DOAJ |
| description | Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy. In two-thirds of patients, it is preceded by an upper respiratory or gastrointestinal tract infection. Temporally associated cases of GBS following COVID-19 vaccination have been described with different COVID-19 vaccines. In this study, we report three cases of GBS patients following COVID-19 vaccine. Two of the studied patients received the Sinopharm vaccine and one patient received the AstraZeneca vaccine. All patients were diagnosed with acute motor axonal neuropathy (AMAN) type of GBS, on nerve conduction studies. All three patients responded well to treatment with intravenous immunoglobulin (IVIg). The association between COVID-19 vaccination and GBS is not well understood and more studies are needed to establish whether it is merely an association or a causal relationship. |
| first_indexed | 2024-03-11T21:41:40Z |
| format | Article |
| id | doaj.art-5fef01a3e576443dab22fa3c2cb19e20 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:41:40Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-5fef01a3e576443dab22fa3c2cb19e202023-09-26T13:19:05ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118510.1080/21645515.2022.20451532045153Post COVID-19 vaccination Guillain-Barre syndrome: three casesSeyedehnarges Tabatabaee0Fatemeh Rezania1Sayed Mohammed Jawad Alwedaie2Ensieh Malekdar3Zahra Badi4Seyed Mohammad Tabatabaei5Zahra Mirzaasgari6Iran university of medical sciencesSt Vincents HospitalMedical university of BahrainMotamedi HospitalErfan HospitalUniversity of TehranIran university of medical sciencesGuillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy. In two-thirds of patients, it is preceded by an upper respiratory or gastrointestinal tract infection. Temporally associated cases of GBS following COVID-19 vaccination have been described with different COVID-19 vaccines. In this study, we report three cases of GBS patients following COVID-19 vaccine. Two of the studied patients received the Sinopharm vaccine and one patient received the AstraZeneca vaccine. All patients were diagnosed with acute motor axonal neuropathy (AMAN) type of GBS, on nerve conduction studies. All three patients responded well to treatment with intravenous immunoglobulin (IVIg). The association between COVID-19 vaccination and GBS is not well understood and more studies are needed to establish whether it is merely an association or a causal relationship.http://dx.doi.org/10.1080/21645515.2022.2045153coronavirus 2019vaccineguillain-barre syndromeastrazenecasinopharm |
| spellingShingle | Seyedehnarges Tabatabaee Fatemeh Rezania Sayed Mohammed Jawad Alwedaie Ensieh Malekdar Zahra Badi Seyed Mohammad Tabatabaei Zahra Mirzaasgari Post COVID-19 vaccination Guillain-Barre syndrome: three cases Human Vaccines & Immunotherapeutics coronavirus 2019 vaccine guillain-barre syndrome astrazeneca sinopharm |
| title | Post COVID-19 vaccination Guillain-Barre syndrome: three cases |
| title_full | Post COVID-19 vaccination Guillain-Barre syndrome: three cases |
| title_fullStr | Post COVID-19 vaccination Guillain-Barre syndrome: three cases |
| title_full_unstemmed | Post COVID-19 vaccination Guillain-Barre syndrome: three cases |
| title_short | Post COVID-19 vaccination Guillain-Barre syndrome: three cases |
| title_sort | post covid 19 vaccination guillain barre syndrome three cases |
| topic | coronavirus 2019 vaccine guillain-barre syndrome astrazeneca sinopharm |
| url | http://dx.doi.org/10.1080/21645515.2022.2045153 |
| work_keys_str_mv | AT seyedehnargestabatabaee postcovid19vaccinationguillainbarresyndromethreecases AT fatemehrezania postcovid19vaccinationguillainbarresyndromethreecases AT sayedmohammedjawadalwedaie postcovid19vaccinationguillainbarresyndromethreecases AT ensiehmalekdar postcovid19vaccinationguillainbarresyndromethreecases AT zahrabadi postcovid19vaccinationguillainbarresyndromethreecases AT seyedmohammadtabatabaei postcovid19vaccinationguillainbarresyndromethreecases AT zahramirzaasgari postcovid19vaccinationguillainbarresyndromethreecases |